Mỹ Đức Hospital
Ho Chi Minh City, 70000, Vietnam
NCT Number: NCT05578118
The investigators follow up on the development of children born from ICSI-AOA using the Developmental Red Flags and Ages & Stages Third Edition (ASQ-3) Questionnaires to give strong evidence about the safety of AOA in assisted reproductive technology.
Looking for future studies?
Notify Me12 month–12 month
All sexes
Observational
Ho Chi Minh City, 70000, Vietnam
Intracytoplasmic sperm injection (ICSI) is the most widely utilized assisted reproductive technique (ART) worldwide. Fertilization rates obtained after ICSI treatment are reported between 70 and 80%, representing the most efficient ART; however, complete post-ICSI fertilization failure still occurs in 3-5% of cases.
The leading cause of failed fertilization is failure to achieve oocyte activation, a crucial stage in the initiation of embryo development during fertilization. Assisted oocyte activation (AOA) using a calcium ionophore has been used for over a decade following ICSI fertilization failure. AOA is not considered a routine practice of ART yet, which is only suitable for patients with proper indications, including (i) total fertilization failure or low fertilization rate (<30%) in the previous IVF; (ii) severe male factor infertility; (iii) patients with a history of embryo arrest or poor embryo quality in previous IVF cycle.
Regarding technique, the artificial rise of induced calcium rises cannot precisely mimic the physiologically sperm-induced calcium oscillations. Little is known yet about the possible adverse effects of ionophores on post-implantation embryo development. Numerous studies have been conducted to compare the development of children born from ICSI - AOA versus non-AOA. Thus, the investigators performed this study to investigate the physical, mental, and motor development of children born following ICSI - AOA using the Developmental Red Flags and Ages & Stages Third Edition (ASQ-3) Questionnaires.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All single, live babies born following ICSI with AOA and ICSI without AOA from 08/2020 to 04/2021.
Parents consent to participate in the study. Group ICSI+AOA: Embryos from ICSI with AOA with calcium ionophore
In the ICSI+AOA group, indications of AOA are:
In the Control group, the indications of AOA for the next IVF cycle (if patients continue the next IVF cycle) are:
Exclusion criteria
Embryos with PGT. Oocyte donation
Time frame: 12 months after birth
ASQ-3 (Ages and Stages Questionaires®) has 5 aspects: Communication, Gross Motor, Fine Motor, Problem-solving, and Personal-Social Each element has 6 questions. If the answer is Yes, score = 10, Sometimes = 5, and Not yet = 0.
ASQ-3 average = average score of 5 aspects.
Time frame: 12 months after birth
6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. Total score will be used: minimum = 0 and maximum = 60. Each aspect in each stage has an alternative threshold.
Time frame: 12 months after birth
6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. Total score will be used: minimum = 0 and maximum = 60. Each aspect in each stage has an alternative threshold.
Time frame: 12 months after birth
6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. Total score will be used: minimum = 0 and maximum = 60. Each aspect in each stage has an alternative threshold.
Time frame: 12 months after birth
6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. Total score will be used: minimum = 0 and maximum = 60. Each aspect in each stage has an alternative threshold.
Time frame: 12 months after birth
6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. Total score will be used: minimum = 0 and maximum = 60. Each aspect in each stage has an alternative threshold.
Time frame: 12 months after birth
For children at 12 months: they
Time frame: 12 months after birth
Duration of breastfeeding
Time frame: 12 months after birth
Infant age at which weaning starts
Time frame: 12 months after birth
Name of diseases that lead to hospital admission
Time frame: 12 months after birth
Number of hospital admission
Time frame: 12 months after birth
Weight on the examination date
Time frame: 12 months after birth
Height on the examination date
Time frame: At birth
Gestational age at delivery
Time frame: At birth
Vaginal birth or C-section
Time frame: At birth
Weight of baby born
Time frame: At birth
Length circumference after birth
Time frame: At birth
Head circumference after birth
Time frame: At birth
Any congenital anomalies detected in baby born
Time frame: Up to 28 days after birth
Number of admission days to NICU
Time frame: Up to 28 days after birth
Respiratory distress syndrome (RDS), diagnosed as the presence of tachypnoea >60/minute, sternal recession and expiratory grunting, need for supplemental oxygen, and a radiological picture of diffuse reticulogranular shadowing with an air bronchogram
Time frame: Up to 28 days after birth
Periventricular haemorrhage II B or worse, will be diagnosed by repeated neonatal cranial ultrasound by the neonatologist according to the guidelines on neuro-imaging described by de Vries et al.
Time frame: Up to 28 days after birth
Necrotizing enterocolitis (NEC) will be diagnosed according to Bell.
Time frame: Up to 28 days after birth
Proven sepsis, will be diagnosed on the combination of clinical signs and positive blood cultures.
Time frame: Up to 28 days after birth
Composite of poor perinatal outcomes, defined as intraventricular haemorrhage, respiratory distress syndrome, necrotizing enterocolitis or neonatal sepsis.
Time frame: Up to 28 days after birth
Any long-term illness and chronic condition appears in a child.
Mỹ Đức Hospital
Other
Physical, Mental, and Motor Development of Children Born From Intracytoplasmic Sperm Injection With Assisted Oocyte Activation With Calcium Ionophore
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05567731
Genital Diseases, GnRH Agonist
Tanta, Egypt
View Trial DetailsNCT04724343
Genital Diseases, In Vitro Fertilization
Damascus, Syria
View Trial DetailsNCT04724486
Genital Diseases, In Vitro Fertilization
Damascus, Syria
View Trial DetailsNCT04727671
Adnexal Diseases, Cysts
Damascus, Syria
View Trial Details